[IgA nephropathy: what you have need to know in 2005]

Details

Serval ID
serval:BIB_39377928826A
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
[IgA nephropathy: what you have need to know in 2005]
Journal
Rev Med Suisse
Author(s)
Cherpillod A., Moll S., Venetz J. P., Halabi G.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2005
Peer-reviewed
Oui
Volume
1
Number
8
Pages
551-4, 556
Language
french
Notes
Cherpillod, A
Moll, S
Venetz, J P
Halabi, G
fre
English Abstract
Review
Switzerland
Rev Med Suisse. 2005 Feb 23;1(8):551-4, 556.
Abstract
Although considered as a benign glomerulopathy, IgA nephropathy (IgAN) is now a well-known cause of end-stage renal disease (ESRD). Fifty percent of people suffering from IgAN developp renal insufficiency and 20 to 30% may reach ESRD after 20 to 25 years of evolution. ACEI is indicated to obtain a thigh control of blood pressure and to reduce proteinuria. Corticosteroids alone or in association with immunosuppressants are indicated for agressive, proliferative form of the disease or when there is an unfavorable outcome despite symptomatic treatment.
Keywords
Glomerulonephritis, IGA/*diagnosis/*drug therapy/epidemiology, Humans, Prognosis
Pubmed
Create date
01/11/2017 12:46
Last modification date
20/08/2019 14:28
Usage data